文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

经导管二尖瓣修复治疗心衰患者3年结局

3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

COAPT试验随机分配614例指南指导药物治疗后仍有症状的中重度继发性二尖瓣反流心衰患者,比较经导管二尖瓣修复联合药物治疗与单用药物治疗。36个月随访显示,修复组心衰住院率和死亡率均显著低于单药组,二尖瓣反流严重程度、生活质量和功能容量持续改善;24个月后交叉接受修复的对照组患者预后与初始修复组相当。

要点

  • 经导管二尖瓣修复降低心衰住院率(年化率35.5% vs 68.8%,HR 0.49)和死亡率(42.8% vs 55.5%,HR 0.67)。
  • 修复组3年二尖瓣反流严重程度、生活质量和功能容量持续改善。
  • 24个月后交叉接受修复的患者死亡或心衰住院复合率低于继续药物治疗者(校正HR 0.43)。

核心结论

  • 对于指南指导药物治疗后仍有症状的中重度或重度继发性二尖瓣反流心衰患者,经导管二尖瓣修复在36个月内安全、持久减少二尖瓣反流,降低心衰住院率并改善生存、生活质量和功能容量。

研究设计与样本

  • COAPT试验随机分配614例心衰伴中重度或重度继发性二尖瓣反流、经最大耐受指南指导药物治疗后仍有症状的患者,比较经导管二尖瓣修复联合药物治疗与单用药物治疗。
  • 主要有效性终点为24个月随访期间所有心衰住院,患者现已随访36个月。

主要发现

  • 经导管二尖瓣修复组与单用药物治疗组年化心衰住院率分别为35.5%和68.8%(HR 0.49;95%CI 0.37-0.63;p<0.001;NNT=3.0;95%CI 2.4-4.0)。
  • 经导管二尖瓣修复组与单用药物治疗组死亡率分别为42.8%和55.5%(HR 0.67;95%CI 0.52-0.85;p=0.001;NNT=7.9;95%CI 4.6-26.1)。
  • 经导管二尖瓣修复组3年二尖瓣反流严重程度、生活质量和功能容量持续改善。
  • 58例初始分配至单用药物治疗后交叉接受经导管二尖瓣修复的患者,其后续死亡或心衰住院复合率低于继续单用药物治疗者(校正HR 0.43;95%CI 0.24-0.78;p=0.006)。

临床怎么用

  • 对于指南指导药物治疗后仍有症状的中重度或重度继发性二尖瓣反流心衰患者,可考虑经导管二尖瓣修复以降低心衰住院和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) resulted in fewer heart failure hospitalizations (HFHs) and lower mortality at 24 months in patients with heart failure (HF) with mitral regurgitation (MR) secondary to left ventricular dysfunction compared with guideline-directed medical therapy (GDMT) alone. OBJECTIVES: This study determined if these benefits persisted to 36 months and if control subjects who were allowed to cross over at 24 months derived similar benefit. METHODS: This study randomized 614 patients with HF with moderate-to-severe or severe secondary MR, who remained symptomatic despite maximally tolerated GDMT, to TMVr plus GDMT versus GDMT alone. The primary effectiveness endpoint was all HFHs through 24-month follow-up. Patients have now been followed for 36 months. RESULTS: The annualized rates of HFHs per patient-year were 35.5% with TMVr and 68.8% with GDMT alone (hazard ratio [HR]: 0.49; 95% confidence interval [CI]: 0.37 to 0.63; p < 0.001; number needed to treat (NNT) = 3.0; 95% CI: 2.4 to 4.0). Mortality occurred in 42.8% of the device group versus 55.5% of control group (HR: 0.67; 95% CI: 0.52 to 0.85; p = 0.001; NNT = 7.9; 95% CI: 4.6 to 26.1). Patients who underwent TMVr also had sustained 3-year improvements in MR severity, quality-of-life measures, and functional capacity. Among 58 patients assigned to GDMT alone who crossed over and were treated with TMVr, the subsequent composite rate of mortality or HFH was reduced compared with those who continued on GDMT alone (adjusted HR: 0.43; 95% CI: 0.24 to 0.78; p = 0.006). CONCLUSIONS: Among patients with HF and moderate-to-severe or severe secondary MR who remained symptomatic despite GDMT, TMVr was safe, provided a durable reduction in MR, reduced the rate of HFH, and improved survival, quality of life, and functional capacity compared with GDMT alone through 36 months. Surviving patients who crossed over to device treatment had a prognosis comparable to those originally assigned to transcatheter therapy. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation [COAPT]; NCT01626079).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mack MJ, Lindenfeld J, Abraham WT, et al. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. J Am Coll Cardiol. 2021. PMID: 33632476. doi:10.1016/j.jacc.2020.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。